Skip to main content

Closed

AVBP: ArriVent BioPharma, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+0.0% / yr

Operating margin0.0%

ROIC-48.4%

Financially safe

Stretched

Debt / equity0.00×

Interest coverage0.0×

Current ratio13.95×

ArriVent BioPharma, Inc.

AVBPNASDAQ Global Market·USD·Closed

ArriVent BioPharma, Inc.

AVBPNASDAQ·USD·Closed

$29.82

−2.74%

$29.82

−$0.84 (2.74%)

52W Range

70thpctl

Volume

0.75×avg

Mkt Cap

1.39BUSD

P/E

-8.4TTM

Div Yield

–ann

52W Range

70thpctl

Volume

0.75×avg

Market Cap

1.39BUSD

P/E Ratio

-8.4TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings